Results 11 to 20 of about 1,727,618 (310)

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus [PDF]

Cell Reports, 2017
Summary: Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing
Katie A. Howell, Jennifer M. Brannan, Christopher Bryan, Andrew McNeal, Edgar Davidson, Hannah L. Turner, Hong Vu, Sergey Shulenin, Shihua He, Ana Kuehne, Andrew S. Herbert, Xiangguo Qiu, Benjamin J. Doranz, Frederick W. Holtsberg, Andrew B. Ward, John M. Dye, M. Javad Aman   +16 more
doaj   +3 more sources

COVID-19: are neutralizing antibodies neutralizing enough? [PDF]

Transfusion, 2020
Kadkhoda K.
europepmc   +5 more sources

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Nature reviews. Immunology, 2022
The ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a number of variants of concern. In this Review, Wang and colleagues discuss progress in the development and characterization of broadly neutralizing ...
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, Huanzhang Zhu, Shibo Jiang, Pengfei Wang   +5 more
semanticscholar   +1 more source

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

Nature reviews. Immunology, 2022
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its ...
B. Haynes, K. Wiehe, P. Borrow, K. Saunders, Bette Korber, K. Wagh, A. McMichael, G. Kelsoe, B. Hahn, F. Alt, G. Shaw   +10 more
semanticscholar   +1 more source

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Higher levels of neutralizing antibodies against KSHV in KS patients compared to asymptomatic individuals from Zambia. [PDF]

PLoS ONE, 2013
Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi Sarcoma (KS), the most common cancer diagnosed in HIV- infected patients.
Pankaj Kumar, Nithal Y Kuwa, Veenu Minhas, Clemence Marimo, Danielle M Shea, Chipepo Kankasa, Charles Wood   +6 more
doaj   +1 more source

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies

Microorganisms, 2022
Vaccination against the SARS-CoV-2 virus or infection with SARS-CoV-2 will lead to the development of IgG antibodies against the S1 protein of the SARS-CoV-2 virus.
Berthold Hocher, Anne Schönbrunn, Xin Chen, Bernhard K. Krämer, Volker von Baehr   +4 more
doaj   +1 more source

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fangzhu Zhao, Deli Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, C. Smith, G. Song, J. Woehl, Linlin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, Stephen A. Rawlings, N. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. Wilson, R. Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Broadly neutralizing antibodies target the coronavirus fusion peptide

bioRxiv, 2022
The potential for future coronavirus outbreaks highlights the need to develop strategies and tools to broadly target this group of pathogens. Here, using an epitope-agnostic approach, we identified six monoclonal antibodies that bound to spike proteins ...
Cherrelle Dacon, C. Tucker, Linghang Peng, C. D. Lee, Ting-Hui Lin, M. Yuan, Yu Cong, Lingshu Wang, Lauren Purser, Jazmean K. Williams, C. Pyo, Ivan Košík, Zhe Hu, Ming Zhao, Divya Mohan, Andrew J. R. Cooper, M. Peterson, J. Skinner, S. Dixit, Erin Kollins, Louis Huzella, Donna L. Perry, R. Byrum, Sanae Lembirik, Yi Zhang, E. Yang, Man Chen, K. Leung, R. Weinberg, A. Pegu, D. Geraghty, E. Davidson, I. Douagi, S. Moir, J. Yewdell, C. Schmaljohn, Peter D. Crompton, M. Holbrook, D. Nemazee, J. Mascola, I. Wilson, Joshua Tan   +41 more
semanticscholar   +1 more source